Arthritis Friendly Commendation Granted to #1 Prescribed
Nasal Spray in Canada
TORONTO, Feb. 26 /CNW Telbec/ - The Arthritis Society today announces its
acknowledgement of the NASONEX(R) (mometasone furoate monohydrate) device as
Arthritis Friendly. NASONEX is the first nasal spray designated with an
easy-to-use commendation for people with arthritis. The Arthritis Society
recognizes products as arthritis friendly once they are evaluated and approved
by an independent lab experienced in the design and evaluation of products for
people with arthritis.
NASONEX is the number one doctor-prescribed nasal spray in Canada(i) and
is approved for use in the treatment of allergic rhinitis (seasonal and
perennial nasal allergies), acute sinusitis as an adjunctive treatment to
antibiotics, and nasal polyps. Rhinitis is an inflammation of the nasal mucous
membranes. It can be allergic, non-allergic or both. Allergic rhinitis affects
approximately 25 per cent of Canadians and can affect people seasonally or
The Arthritis Society's Arthritis Friendly Product Program encourages
manufacturers to design user-friendly products and packaging. "Arthritis
imposes many barriers to daily living and we are working hard to make the life
of people living with arthritis easier, says Steven McNair, President and CEO,
The Arthritis Society. In this context, The Arthritis Society is proud to
recognize NASONEX with an arthritis friendly commendation."
"Allergies affect people in all walks of life and it is my goal to ensure
that patients are receiving optimal treatment of their allergy symptoms. I'm
pleased that my patients who live with the daily challenges of arthritis can
get the relief they need and have a better quality of life. If my arthritis
patients find the device easy-to-use, then I'm confident my other patients
will also benefit from this advantage." says Dr. Francois Lavigne,
Otolaryngologist and adjunct professor at the Centre hospitalier de
l'Université de Montréal, Hôpital Notre-Dame.
About The Arthritis Society
The Arthritis Society is Canada's primary health charity which empowers
the nearly 4.5 million Canadians with arthritis to live their lives to the
fullest by combating the daily limitations of arthritis. Over the last
60 years, The Society has invested $160 million towards arthritis research to
develop better treatments and ultimately find a cure. The Arthritis Society's
website is www.arthritis.ca.
NASONEX is a nasal-inhaled steroid related to cortisol, a hormone
produced naturally by the body(ii). NASONEX works by reducing inflammation
caused by allergies, relieving bothersome symptoms such as nasal congestion.
In addition to providing relief for allergy sufferers, NASONEX is unscented
and contains glycerol, a soothing emollient or moisturizer.
With over 9 million patient years of experience(iii), Nasonex is the
number one prescribed nasal steroid in Canada(iv). NASONEX is approved to
treat the symptoms of seasonal or perennial allergic rhinitis in adults,
adolescents, and children between the ages of three and 11 years. NASONEX is
also approved by Health Canada for the treatment of acute episodes of
sinusitis, as adjunctive treatment to antibiotics, in adults and children
12 years of age and older, as well as the treatment of nasal polyps for adults
18 years and older.
About Schering-Plough Canada Inc.
Schering-Plough Canada Inc. is a country operation of Schering-Plough
Corporation that employs over 950 people across Canada. Schering-Plough Canada
Inc.'s web site is www.schering-plough.ca.
Schering-Plough is an innovation-driven, science-centered global health
care company. Through its own biopharmaceutical research and collaborations
with partners, Schering-Plough creates therapies that help save and improve
lives around the world. The company applies its research-and-development
platform to human prescription and consumer products as well as to animal
health products. In November 2007, Schering-Plough acquired Organon
BioSciences, with its Organon human health and Intervet animal health
businesses, marking a pivotal step in the company's ongoing transformation.
Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors,
patients, customers and other stakeholders served by its approximately
50,000 people around the world. The company is based in Kenilworth, N.J.,
U.S.A. and its Web site is www.schering-plough.com.
i Flash Report Pharmaceutical Care. Nov. 2007. Nasal Anti-Allergy PREPS
ii NASONEX(R) Product Information. Schering Corporation.
iii Flash Report Pharmaceutical Care. Nov. 2007. Nasal Anti-Allergy PREPS
iv Flash Report Pharmaceutical Care. Nov. 2007. Nasal Anti-Allergy PREPS
NASONEX(R) is a registered trademark of Schering-Plough Canada Inc.
For further information:
For further information: Sinead Canavan, The Arthritis Society, (416)
979-7228 ext 348, email@example.com; Kent Hovey-Smith, Schering-Plough
Canada Inc., (514) 428-7475, firstname.lastname@example.org; Daphne Weatherby,
Edelman, (514) 844-6665, ext. 225, email@example.com